ArticleCell death discovery2022

Targeting ADRB2 enhances sensitivity of non-small cell lung cancer to VEGFR2 tyrosine kinase inhibitors.

Yingzhuo Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.